A double-blind, placebo-controlled, first in human, single- ascending dose and a 14-day multiple-ascending dose phase 1 study in healthy subjects to determine the safety, tolerability, pharmacokinetics and pharmacodynamics (PD) of MET409
Latest Information Update: 04 Jul 2019
At a glance
- Drugs MET-409 (Primary)
- Indications Inflammatory bowel diseases; Irritable bowel syndrome; Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Metacrine
- 02 Jul 2019 According to an Metacrine media release, the initial clinical data in nonalcoholic steatohepatitis (NASH) patients will be presented in a poster presentation at the Paris NASH Meeting 2019.
- 02 Jul 2019 Results published in the Metacrine Media Release.
- 13 Jun 2018 According to a Metacrine media release, dosing of the first cohort has been completed in this trial.